Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMedOpen access

[Stem cell therapy for premature ovarian insufficiency: a review of clinical evidence and therapeutic strategies].

Cheng Z., Lai D.

Narrative Review on Hair & Scalp, published in Zhejiang Da Xue Xue Bao Yi Xue Ban (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Zhejiang Da Xue Xue Bao Yi Xue Ban (2025)
Country
China
Reported sample size
—
Source database
PubMed
PMID
41260722
PMCID
PMC12750048
DOI
10.3724/zdxbyxb-2025-0148

Abstract (original English)

Premature ovarian insufficiency (POI), characterized by the decline of ovarian function before age 40, significantly compromises fertility and long-term health of patients. Stem cell therapy has emerged as a promising approach for POI. This review synthesizes clinical evidence from studies utilizing cells sourced from adult tissues (e.g., adipose-derived mesenchymal stem cells, bone marrow mesenchymal stem cells and peripheral blood stem cells) as well as from perinatal tissues (e.g., human amniotic epithelial cells and umbilical cord-derived mesenchymal stem cells). Evidence suggests that stem cell transplantation can improve ovarian reserve, reflected by reduced follicle-stimulating hormone levels and increased estradiol and anti-Müllerian hormone levels, with some patients resuming menstruation and achieving pregnancy. However, treatment efficacy is influenced by patient-specific factors and clinical protocols. Optimizing stem cell transplantation protocols is pivotal for enhancing the clinical efficacy and safety. This article elaborates on key optimization strategies, including transplantation timing, delivery routes, and combination therapies, proposing that early intervention and person-alized regimens may improve outcomes. We also discuss patient benefits (such as pregnancy outcomes and quality of life) as well as treatment safety, and explore the clinical value of stem

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansPrimary Ovarian InsufficiencyFemaleStem Cell TransplantationMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research